Chinese Journal of Antituberculosis ›› 2026, Vol. 48 ›› Issue (5): 716-622.doi: 10.19982/j.issn.1000-6621.20250474
• Review Articles • Previous Articles Next Articles
Lai Xiaoyu, Liao Qinghua, Wen Wenpei(
), Guo Huixin, Lin Weibin, Chen Xunxun(
)
Received:2025-12-02
Online:2026-05-10
Published:2026-04-27
Contact:
Wen Wenpei,Chen Xunxun
E-mail:grace_chen514@163.com;wwp_yb@126.com
Supported by:CLC Number:
Lai Xiaoyu, Liao Qinghua, Wen Wenpei, Guo Huixin, Lin Weibin, Chen Xunxun. Advances in the research on the pathogenesis of tuberculous uveitis[J]. Chinese Journal of Antituberculosis, 2026, 48(5): 716-622. doi: 10.19982/j.issn.1000-6621.20250474
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20250474
| [1] | Alli HD, Ally N, Mayet I, et al. Global prevalence and clinical outcomes of tubercular uveitis: a systematic review and meta-analysis. Surv Ophthalmol, 2022, 67(3):770-792. doi:10.1016/j.survophthal.2021.10.001. |
| [2] |
Standardization of Uveitis Nomenclature (SUN) Working Group. Classification Criteria for Tubercular Uveitis. Am J Ophthalmol, 2021, 228:142-151. doi:10.1016/j.ajo.2021.03.040.
pmid: 33845014 |
| [3] |
Aggarwal K, Agarwal A, Deokar A, et al. Ultra-Wide Field Imaging in Paradoxical Worsening of Tubercular Multifocal Serpiginoid Choroiditis after the Initiation of Anti-Tubercular Therapy. Ocul Immunol Inflamm, 2019, 27(3):365-370. doi:10.1080/09273948.2017.1373829.
pmid: 29020501 |
| [4] | Betzler BK, Gunasekeran DV, Kempen J, et al. The Historical Evolution of Ocular Tuberculosis: Past, Present, and Future. Ocul Immunol Inflamm, 2022, 30(3):593-599. doi:10.1080/09273948.2021.1992446. |
| [5] |
Agrawal R, Gunasekeran DV, Grant R, et al. Clinical Features and Outcomes of Patients With Tubercular Uveitis Treated With Antitubercular Therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1. JAMA Ophthalmol, 2017, 135(12):1318-1327. doi:10.1001/jamaophthalmol.2017.4485.
pmid: 29075752 |
| [6] | Albert DM, Raven ML. Ocular tuberculosis. Microbiol Spectr, 2016, 4 (6):TNMI7-0001-2016. doi:10.1128/microbiolspec.TNMI7-0001-2016. |
| [7] | Koch R. Professor Koch’s remedy for tuberculosis: A further communication on a remedy for tuberculosis. Indian J Med Res, 2023, 157(2/3):169-173. doi:10.4103/0971-5916.373948. |
| [8] |
Woods AC, Wood RM, Naquin HA. Studies in experimental ocular tuberculosis. Effect of streptomycin and promizole in experimental ocular tuberculosis in the normal rabbit. Arch Ophthal, 1950, 43(5):834-844.
pmid: 15414081 |
| [9] | Coelho Filho JC, Takenami I, Arruda S. Revisiting the Rich’s formula: an update about granulomas in human tuberculosis. Braz J Infect Dis, 2013, 17(2):234-238. doi:10.1016/j.bjid.2013.01.006. |
| [10] | Abdisamadov A, Tursunov O. Ocular tuberculosis epidemiology, clinic features and diagnosis: A brief review. Tuberculosis (Edinb), 2020, 124:101963. doi:10.1016/j.tube.2020.101963. |
| [11] | Chawla R, Singh MK, Singh L, et al. Tubercular DNA PCR of ocular fluids and blood in cases of presumed ocular tuberculosis: a pilot study. Ther Adv Ophthalmol, 2022, 14:25158414221123522. doi:10.1177/25158414221123522. |
| [12] | Sharma K, Sharma M, Joshi H, et al. Evaluation of Mycobacterium Tuberculosis Derived Cell-Free DNA-Based Multi-Targeted Real-Time PCR from Vitreous Fluid (VF) Samples to Diagnose Ocular Tuberculosis. Ocul Immunol Inflamm, 2025, 33(9):1907-1912. doi:10.1080/09273948.2025.2532820. |
| [13] | Putera I, Schrijver B, Ten Berge JCEM, et al. The immune response in tubercular uveitis and its implications for treatment: From anti-tubercular treatment to host-directed therapies. Prog Retin Eye Res, 2023, 95:101189. doi:10.1016/j.preteyeres.2023.101189. |
| [14] | Damera SK, Panigrahi RK, Mitra S, et al. Role of Extracellular Mycobacteria in Blood-Retinal Barrier Invasion in a Zebrafish Model of Ocular TB. Pathogens, 2021, 10(3):333. doi:10.3390/pathogens10030333. |
| [15] | Dalvin LA, Smith WM. Intraocular manifestations of mycobacterium tuberculosis: A review of the literature. J Clin Tuberc Other Mycobact Dis, 2017, 7:13-21. doi:10.1016/j.jctube.2017.01.003. |
| [16] |
Aggarwal K, Agarwal A, Sehgal S, et al. An unusual presentation of intraocular tuberculosis in a monocular patient: clinicopathological correlation. J Ophthalmic Inflamm Infect, 2016, 6 (1): 46. doi:10.1186/s12348-016-0118-8.
pmid: 27888495 |
| [17] | Basu S, Elkington P, Rao NA. Pathogenesis of ocular tuberculosis: New observations and future directions. Tuberculosis (Edinb), 2020, 124:101961. doi:10.1016/j.tube.2020.101961. |
| [18] |
Yeh S, Sen HN, Colyer M, et al. Update on ocular tuberculosis. Curr Opin Ophthalmol, 2012, 23(6):551-556. doi:10.1097/ICU.0b013e328358ba01.
pmid: 23047173 |
| [19] |
Kataria P, Kumar A, Bansal R, et al. devR PCR for the diagnosis of intraocular tuberculosis. Ocul Immunol Inflamm, 2015, 23(1):47-52. doi:10.3109/09273948.2014.981550.
pmid: 25615810 |
| [20] | Sharma K, Gupta A, Sharma M, et al. Detection of viable Mycobacterium tuberculosis in ocular fluids using mRNA-based multiplex polymerase chain reaction. Indian J Med Microbiol, 2022, 40(2):254-257. doi:10.1016/j.ijmmb.2021.12.019. |
| [21] |
Konana VK, Babu K. Current concepts in the diagnosis of ocular tuberculosis: A narrative review. Taiwan J Ophthalmol, 2025, 15 (2): 203-211. doi:10.4103/tjo.TJO-D-24-00115.
pmid: 40584192 |
| [22] |
Balne PK, Modi RR, Choudhury N, et al. Factors influencing polymerase chain reaction outcomes in patients with clinically suspected ocular tuberculosis. J Ophthalmic Inflamm Infect, 2014, 4(1):10. doi:10.1186/1869-5760-4-10.
pmid: 24661354 |
| [23] | Kaur K, Laal S, Ryndak MB. Mycobacterium tuberculosis transcriptome in intraocular tuberculosis. J Med Microbiol, 2023, 72(2). doi:10.1099/jmm.0.001649. |
| [24] |
Ganesh SK, Abraham S, Sudharshan S. Paradoxical reactions in ocular tuberculosis. J Ophthalmic Inflamm Infect, 2019, 9(1):19. doi:10.1186/s12348-019-0183-x.
pmid: 31493128 |
| [25] |
Ohara H, Harada Y, Hiyama T, et al. Incidence of ocular inflammation among patients with active tuberculosis or nontuberculous mycobacterial infections in a tertiary hospital in Japan. Int Ophthalmol, 2021, 41(4):1427-1436. doi:10.1007/s10792-021-01718-z.
pmid: 33475908 |
| [26] | Multani PK, Modi R, Basu S. Pattern of Recurrent Inflammation following Anti-tubercular Therapy for Ocular Tuberculosis. Ocul Immunol Inflamm, 2022, 30(1):185-190. doi:10.1080/09273948.2020.1772838. |
| [27] | Fernández-Zamora Y, Finamor LP, Silva LMP, et al. Role of Interferon-Gamma Release Assay for the Diagnosis and Clinical Follow up in Ocular Tuberculosis. Ocul Immunol Inflamm, 2023, 31(2):304-311. doi:10.1080/09273948.2022.2027459. |
| [28] | Alam K, Sharma G, Forrester JV, et al. Antigen-Specific Intraocular Cytokine Responses Distinguish Ocular Tuberculosis From Undifferentiated Uveitis in Tuberculosis-Immunoreactive Patients. Am J Ophthalmol, 2023, 246:31-41. doi:10.1016/j.ajo.2022.08.029. |
| [29] | Shree R, Mahesh KV, Takkar A, et al. The Neuro-Ophthalmology of Tuberculosis. Neuroophthalmology, 2023, 48(2):73-92. doi:10.1080/01658107.2023.2281435. |
| [30] | Gusmão CC, Dos Reis R, Litvoc MN, et al. Paradoxical Reaction in Intraocular Tuberculosis: Report of Three Cases. Ocul Immunol Inflamm, 2024, 32(10):2562-2567. doi:10.1080/09273948.2024.2372314. |
| [31] | Kon OM, Beare N, Connell D, et al. BTS clinical statement for the diagnosis and management of ocular tuberculosis. BMJ Open Respir Res, 2022, 9(1):e001225. doi:10.1136/bmjresp-2022-001225. |
| [32] | Biswas J, Therese L, Madhavan HN. Use of polymerase chain reaction in detection of Mycobacterium tuberculosis complex DNA from vitreous sample of Eales’ disease. Br J Ophthalmol, 1999, 83(8):994. doi:10.1136/bjo.83.8.994. |
| [33] | Agrawal R, Testi I, Rousselot A, et al. Insights into the molecular pathogenesis of ocular tuberculosis. Tuberculosis (Edinb), 2021, 126:102018. doi:10.1016/j.tube.2020.102018. |
| [34] | Nandi K, Panda AK, Chakraborty A, et al. Role of ATP-Small Heat Shock Protein Interaction in Human Diseases. Front Mol Biosci, 2022, 9:844826. doi:10.3389/fmolb.2022.844826. |
| [35] | Kutlutürk Karagöz I, Kaya M, Kıvrak U, et al. Exploring the Molecular Intersection of Posterior Ocular Tuberculosis: Mycobacterium tuberculosis Proteins, Ocular Autoimmunity, and Immune Receptor Interactions. Ophthalmol Sci, 2024, 5(3):100698. doi:10.1016/j.xops.2024.100698. |
| [36] |
Wroblewski KJ, Hidayat AA, Neafie RC, et al. Ocular tuberculosis: a clinicopathologic and molecular study. Ophthalmology, 2011, 118(4):772-777. doi:10.1016/j.ophtha.2010.08.011.
pmid: 21055814 |
| [37] | Adamus G. Are Anti-Retinal Autoantibodies a Cause or a Consequence of Retinal Degeneration in Autoimmune Retinopa-thies?. Front Immunol, 2018, 9:765. doi:10.3389/fimmu.2018.00765. |
| [38] | Wildner G, Diedrichs-Möhring M. Molecular Mimicry and Uveitis. Front Immunol, 2020, 11:580636. doi:10.3389/fimmu.2020.580636. |
| [39] | Zhang YK, Guan Y, Zhao J, et al. Diagnosis of tuberculous uveitis by the macrogenome of intraocular fluid: A case report and review of the literature. World J Clin Cases, 2023, 11(14):3248-3255. doi:10.12998/wjcc.v11.i14.3248. |
| [40] |
Papasavvas I, Jeannin B, Herbort CP. Tuberculosis-related serpiginous choroiditis: aggressive therapy with dual concomitant combination of multiple anti-tubercular and multiple immunosuppressive agents is needed to halt the progression of the disease. J Ophthalmic Inflamm Infect, 2022, 12(1):7. doi:10.1186/s12348-022-00282-6.
pmid: 35132499 |
| [41] | Brar M, Sharma M, Grewal S, et al. Longitudinal study of serpiginous choroiditis and serpiginous like choroiditis using wide field OCT angiography. Eur J Ophthalmol, 2022, 32(3):1555-1561. doi:10.1177/11206721211028529. |
| [42] | Shah JS, Shetty N, Shah SK, et al. Tubercular Uveitis with Ocular Manifestation as the First Presentation of Tuberculosis: A Case Series. J Clin Diagn Res, 2016, 10(3):NR01-3. doi:10.7860/JCDR/2016/16219.7375. |
| [43] | 赖晓宇, 段鸿飞, 陈珣珣, 等. 结核性葡萄膜炎临床特征,诊断策略与分级标准研究进展. 中国防痨杂志, 2025, 47(9):1204-1211. doi:10.19982/j.issn.1000-6621.20250196. |
| [44] | Welin A, Björnsdottir H, Winther M, et al. CFP-10 from Mycobacterium tuberculosis selectively activates human neutrophils through a pertussis toxin-sensitive chemotactic receptor. Infect Immun, 2015, 83(1):205-213. doi:10.1128/IAI.02493-14. |
| [45] |
Renshaw PS, Lightbody KL, Veverka V, et al. Structure and function of the complex formed by the tuberculosis virulence factors CFP-10 and ESAT-6. EMBO J, 2005, 24(14):2491-2498. doi:10.1038/sj.emboj.7600732.
pmid: 15973432 |
| [46] | van Leeuwen LM, Boot M, Kuijl C, et al. Mycobacteria employ two different mechanisms to cross the blood-brain barrier. Cell Microbiol, 2018, 20(9):e12858. doi:10.1111/cmi.12858. |
| [47] | Liu R, Dang JN, Lee R, et al. Mycobacterium dormancy and antibiotic tolerance within the retinal pigment epithelium of ocular tuberculosis. Microbiol Spectr, 2024, 12(8):e0078824. doi:10.1128/spectrum.00788-24. |
| [48] | 程奕喆, 呼风, 王茹, 等. 结核性葡萄膜炎患者房水的细胞因子含量研究. 眼科, 2023, 32(2):135-141. doi:10.13281/j.cnki.issn.1004-4469.2023.02.009. |
| [49] |
Ang M, Cheung G, Vania M, et al. Aqueous cytokine and chemokine analysis in uveitis associated with tuberculosis. Mol Vis, 2012, 18:565-573.
pmid: 22509092 |
| [50] | Putera I, La Distia Nora R, Ten Berge JCEM, et al. Diagnostic Biomarkers for Uveitis: Serum BAFF and CXCL 9 in Differentiating Ocular Sarcoidosis, Tuberculosis and Other Entities with Implication for QuantiFERON-Positive Uveitis. Ocul Immunol Inflamm, 2025, 33(8):1548-1560. doi:10.1080/09273948.2025.2493357. |
| [51] | Valenzuela RA, Vega-Tapia F, Elizalde N, et al. IL-10 and IL-6/IL-10 as predictive biomarkers for treatment response in non-infectious uveitis. Front Immunol, 2025, 16:1584905. doi:10.3389/fimmu.2025.1584905. |
| [52] | Chadalawada S, Kathirvel K, Lalitha P, et al. Dysregulated expression of microRNAs in aqueous humor from intraocular tuberculosis patients. Mol Biol Rep, 2022, 49(1):97-107. doi:10.1007/s11033-021-06846-4. |
| [53] | Davuluri KS, Chauhan DS. microRNAs associated with the pathogenesis and their role in regulating various signaling pathways during Mycobacterium tuberculosis infection. Front Cell Infect Microbiol, 2022, 12:1009901. doi:10.3389/fcimb.2022.1009901. |
| [54] |
Li R, Zheng SG, Zhou H. Metabolomics of ocular immune diseases. Metabolomics, 2025, 21(3):74. doi:10.1007/s11306-025-02273-9.
pmid: 40457094 |
| [55] | 肖媛媛, 毛羽, 曹绪胜, 等. 结核性葡萄膜炎初始抗结核治疗矛盾反应的临床特征. 眼科, 2022, 31(4):277-281. doi:10.13281/j.cnki.issn.1004-4469.2022.04.006. |
| [56] | Quinn CM, Poplin V, Kasibante J, et al. Tuberculosis IRIS: Pathogenesis, Presentation, and Management across the Spectrum of Disease. Life (Basel), 2020, 10(11):262. doi:10.3390/life10110262. |
| [57] | Nieto-Aristizábal I, Mera JJ, Giraldo JD, et al. From ocular immune privilege to primary autoimmune diseases of the eye. Autoimmun Rev, 2022, 21(8):103122. doi:10.1016/j.autrev.2022.103122. |
| [58] | Woodward R, Konda SM, Grewal DS. Autoimmune Inflammatory Eye Disease: Demystifying Clinical Presentations for the Internist. Curr Allergy Asthma Rep, 2023, 23(8):471-479. doi:10.1007/s11882-023-01088-9. |
| [59] |
Sharma RK, Sharma J, Khan ZK, et al. Diminished TLR2-TLR9 mediated CD4+ T cell responses are associated with increased inflammation in intraocular tuberculosis. Sci Rep, 2018, 8(1): 13812. doi:10.1038/s41598-018-32234-3.
pmid: 30218032 |
| [60] |
Basu S, Hassman L, Kodati S, et al. Intraocular Immune Response in Human Uveitis: Time to Look Beyond Animal Models. Am J Ophthalmol, 2024, 266:17-25. doi:10.1016/j.ajo.2024.04.026.
pmid: 38703799 |
| [61] | Tagirasa R, Parmar S, Barik MR, et al. Autoreactive T Cells in Immunopathogenesis of TB-Associated Uveitis. Invest Ophthalmol Vis Sci, 2017, 58(13):5682-5691. doi:10.1167/iovs.17-22462. |
| [1] | Gao Li, Zhang Guoqin. Current status and optimization paths of latent tuberculosis infection screening in patients with rheumatic immune diseases in China [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 561-566. |
| [2] | Huang Guojun, Wang Qiqi, Zheng Wenjing, Liu Jianjun, Bai Liqiong, Liang Jun, Yu Shicheng, Xu Zuhui, Wan Yanping, Liu Xie, Yao Hongyan, Ming Hui. Trend of pulmonary tuberculosis reported incidence in Hunan Province from 2009 to 2023: a population-based study using Joinpoint regression model [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 567-575. |
| [3] | Che Yang, Zhang Dongliang, Li Xiangchen, Lu Yewei, Liu Zhengwei. Molecular characterization and risk factors of cross-resistance between isoniazid and prothionamide in multidrug-resistant Mycobacterium tuberculosis in Ningbo, China [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 576-585. |
| [4] | Sun Zheng, Liu Jiongya, Chen Chi, Yu Quanji, Li Yanan, Chen Cheng, Zhu Limei. Study on the application of AI-assisted CT reading system in early detection of pulmonary tuberculosis in general hospitals [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 586-593. |
| [5] | Xie Cifu, Yin Pengliang, Song Lixin, Xiong Zi. Analysis of out-of-pocket medical expenses and influencing factors of multidrug-resistant/rifampicin-resistant pulmonary tuberculosis patients in Changsha City [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 594-602. |
| [6] | Wu Yaning, Huang Misun, Guo Yi, Bo Xianglong, Wang Ruihuan, Xing Jianliang, Fan Xueting, Xu Da, Zhao Lili, Zhao Xiuqin, Li Guilian, Liu Haican, Li Machao. Analysis of genetic mutation characteristics associated with linezolid resistance in Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 603-615. |
| [7] | Wu Gang, Zhang Zhengbin, Lu Zhouqin, Wang Xiaojun, Zhou Meilan, Li Yuehua. Comparison of clinical application effect between a novel fluorescent probe-based PCR method and three laboratory methods for detecting the Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 616-620. |
| [8] | Huang Jun, Du Zhixiang, Hu Chunmei. Influence factors of metabolic dysfunction-associated fatty liver disease on short-term effectiveness of anti-tuberculosis therapy in primary pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 631-640. |
| [9] | Zhang Shanshan, Han Yaxuan, Zhang Xiaoyan, Li Jianying, Ren Fei, Zhang Yaohui, Yang Haixia. Clinical characteristics and survival analysis of patients with lung cancer concurrent with drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 641-650. |
| [10] | Meng Ting, Chen Jingfang, Deng Guofang, Lin Yi, Yuan Jinsong, Ma Mengting. Analysis of current status of mental vulnerability of tuberculosis patients and its influencing factors [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 651-660. |
| [11] | Gao Dan, Yao Liwei, Huang Jinpeng, Liu Xiaoxia, Zhang Yue, Ling Lin. Evidence summary on hospital-family digital health management with integrated traditional Chinese and Western medicine for tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 661-669. |
| [12] | Zhao Xiaoting, Han Jing, Hou Zhili, Ding Wenlong, Zhang Yuyang, Zhang Shuo, Xing Zhiheng. Predictive value of baseline chest CT features for anti-tuberculosis treatment outcomes in patients with non-drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 670-676. |
| [13] | Yang Bin, Cao Yuqing, Zong Xingyu, Wang Chaohong, Zhao Liping, Su Dahong, Gong Mengmeng, Ma Yan, Shi Yiheng, Lin Weibing, Zhao Jinfeng, Cheng Simin, Miao Tiantian, Wang Guirong. Mechanism of Tounong San in abscess-type lymph node tuberculosis treatment using network pharmacology [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 677-686. |
| [14] | Li Qin, Li Linhong, Liu Jiao, Feng Mei, Xie Qi, Zhang Guixian, Yang Qiong, Yang Dandan. A case of AIDS with rifampicin-resistant tuberculous breast abscess and literature review [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 687-693. |
| [15] | Hu Xinyang, Liu Yang, Gao Jingtao. Research progress on latent tuberculosis infection in patients with hematological malignancies [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 694-699. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.